MET是致癌基因，编码蛋白是一种受体酪氨酸激酶，是一个单次跨膜酪氨酸受体蛋白。MET是普遍表达的细胞表面受体，其与细胞外HGF结合，导致几种下游细胞内途径的活化。这些活化途径包括PI3K / AKT和RAS / RAF / MEK，其促进细胞生长和增殖，运动，迁移和血管生成。在各种上皮癌中观察到MET通过基因扩增，胚系或体细胞突变或受体过度表达的失调，包括乳腺癌，前列腺癌，非小细胞肺癌 ，肾乳头状癌，肝细胞癌和胃癌。

MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.The Mesenchymal Epithelial Transition (MET) proto-oncogene encodes the MET receptor tyrosine kinase, also called c-MET or hepatocyte growth factor (HGF) receptor. MET is a ubiquitously expressed cell surface receptor that binds to extracellular HGF, leading to the activation of several downstream intracellular pathways. These include the PI3K/AKT and RAS/RAF/MEK pathways, which promote cellular growth and proliferation, motility, migration and angiogenesis. Dysregulation of MET via gene amplification, germline or somatic mutations or receptor overexpression has been observed in a variety of epithelial cancers, including breast, prostate cancer, non-small cell lung cancer, renal papillary carcinoma, hepatocellular and gastric carcinomas.

GeneCards OncoKB My Cancer Genome